Global Penny Stocks To Watch In August 2026

As global markets continue to navigate a complex landscape marked by record highs in major U.S. stock indexes and evolving geopolitical scenarios, investors are increasingly exploring diverse opportunities. Penny stocks, often seen as the domain of smaller or emerging companies, remain a compelling segment for those looking to uncover potential growth at an affordable entry point. Despite being considered an outdated term by some, penny stocks can still offer significant opportunities when backed by strong financials; here we highlight three such stocks that merit attention for their potential to deliver substantial returns.

Let's take a closer look at a couple of our picks from the screened companies.

Ajman Bank PJSC (DFM:AJMANBANK)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Ajman Bank PJSC offers a range of banking products and services to individuals, businesses, and government institutions in the United Arab Emirates, with a market cap of AED3.83 billion.

Operations: The company's revenue is primarily derived from its Wholesale Banking segment at AED509.65 million, followed by Consumer Banking at AED274.71 million and Treasury operations contributing AED182.11 million.

Market Cap: AED3.83B

Ajman Bank PJSC demonstrates certain appealing characteristics for investors interested in penny stocks. With a market cap of AED3.83 billion, the bank's price-to-earnings ratio of 7.6x is below the UAE market average, indicating potential value. Recent earnings show growth, with net income rising to AED116.85 million in Q2 2026 from AED110.42 million a year ago, and stable basic earnings per share at AED0.091 for six months ended June 2026. The bank maintains an appropriate loans-to-deposits ratio of 72%, although it faces challenges with high non-performing loans at 5.9%. Despite these issues, Ajman Bank's earnings have grown significantly over five years by an average of 31.9% annually and continue to exceed industry growth rates.

• Click to explore a detailed breakdown of our findings in Ajman Bank PJSC's financial health report.
• Gain insights into Ajman Bank PJSC's past trends and performance with our report on the company's historical track record.

Tatwah SmartechLtd (SZSE:002512)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Tatwah Smartech Co., Ltd. operates in the communication networks, digital screens, and digital application services sectors both in China and internationally, with a market capitalization of CN¥4.12 billion.

Operations: Revenue Segments: No Revenue Segments Reported

Market Cap: CN¥4.12B

Tatwah Smartech Ltd. presents a mixed picture for investors in penny stocks, with a market cap of CN¥4.12 billion and no reported revenue segments, indicating it may be pre-revenue. Despite being unprofitable, the company has managed to reduce its debt to equity ratio significantly over five years and maintains a satisfactory net debt to equity ratio of 19.6%. The management team is seasoned with an average tenure of 5.6 years, suggesting stability in leadership. Although short-term liabilities exceed assets, the firm has a positive cash flow runway extending beyond three years due to growing free cash flow.

• Take a closer look at Tatwah SmartechLtd's potential here in our financial health report.
• Review our historical performance report to gain insights into Tatwah SmartechLtd's track record.

Fuan Pharmaceutical (Group) (SZSE:300194)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Fuan Pharmaceutical (Group) Co., Ltd. is engaged in the research, development, production, and sale of chemical drugs both in China and internationally, with a market cap of CN¥4.76 billion.

Operations: The company generates its revenue primarily from the pharmaceutical industry, amounting to CN¥1.68 billion.

Market Cap: CN¥4.76B

Fuan Pharmaceutical (Group) Co., Ltd. offers a complex profile for penny stock investors, with a market cap of CN¥4.76 billion and revenue of CN¥1.68 billion from the pharmaceutical sector. The company has experienced management, averaging 15.3 years in tenure, and its board is also seasoned with an average tenure of 4.7 years. Despite reducing its debt to equity ratio over five years and having more cash than total debt, Fuan faces challenges like a significant one-off loss impacting recent financials and declining profit margins from 11% to 3.7%. The dividend yield of 1.75% is not well covered by earnings.

• Unlock comprehensive insights into our analysis of Fuan Pharmaceutical (Group) stock in this financial health report.
• Evaluate Fuan Pharmaceutical (Group)'s historical performance by accessing our past performance report.

Turning Ideas Into Actions

• Gain an insight into the universe of 3,614 Global Penny Stocks by clicking here.
• Want To Explore Some Alternatives? Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com